Ondansetron is the officially recommended active ingredient (Anti 5 HT3 - receptor) for treating nausea and vomiting caused by chemotherapy-induced cell toxicity, radiation therapy, or postoperative nausea and vomiting (PONV). This medication is safe and is included in treatment protocols for children aged 1 month and older after surgery or for children aged 6 months and older undergoing chemotherapy and radiation therapy.
Furthermore, scientific research and clinical guidelines consistently endorse the off-label use of ondansetron in treating gastrointestinal-related nausea and vomiting, particularly in children with acute gastroenteritis.